ArticleFrontiers in microbiology2025
Dual function of
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteomyelitis is a chronic inflammation of bone due to pathogenic infection mainly by methicillin-resistant Methods: We phyto-fabricated gold nanoparticles using plant extract from Results: DR-AuNPs displayed substantial antibacterial activity against MRSA-induced osteomyelitis by increasing ROS production, membrane leakage, membrane permeability, and disruption of surface structure in the MRSA. Several anti-biofilm assays and electron microscopic studies have demonstrated the efficacy of DR-AuNPs in significantly inhibiting the formation of MRSA biofilm. Interestingly, DR-AuNPs were also found to promote the lineage commitment of bone marrow-derived mesenchymal stem cells (BMSCs) into osteoblasts Discussion: Our data provide green DR-AuNPs with dual antibacterial and osteoinductive activities, making them a promising bioactive agent for managing osteomyelitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.